Recent Company News

• 01:57 AM ET Jul 09, 2026
  

  ABL Bio receives FDA approval of IND amendment to initiate phase 1 trial of ABL503 (KRW 81700.0000, +200)

• 08:21 AM ET Apr 29, 2026
  

  StreetAccount Summary - US Pre-market trading

• 11:10 AM ET Jul 02, 2026
  

  StreetAccount Summary - US unusual volume traders

• 07:07 AM ET Jun 29, 2026
  

  NovaBridge Biosciences CEO Xi-Yong (Sean) Fu to step down ($1.64, 0.00)

• 07:02 AM ET Jun 16, 2026
  

  NovaBridge receives FDA Fast Track Designation for Givastomig in first-line HER2-negative metastatic gastric cancer ($1.47, 0.00)

• 10:03 AM ET Jun 11, 2026
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (204 total)

• 10:05 AM ET Jun 08, 2026
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (168 total)

• 03:49 PM ET Jun 04, 2026
  

  Transcript Intelligence: NovaBridge Biosciences at Jefferies Global Healthcare Conference ($1.80, +0.04)